CL2016000982A1 - Compuestos derivados de 1,4-dihidrocromeno[4,3-c]-pirazol, 1h-pirazol[4,3-f o 3,4-f]-quinolina, 1h-benzo[g]-indazol, que median una afección por fxr; composiciones y combinaciones farmacológicas; útiles para el tratamiento de una enfermedad hepática, tales como colestasis intrahepática, inducida por los estrógenos, por fármacos, inducida por fármacos, asociada al embarazo, asociada a nutrición parenteral, entre otras. - Google Patents

Compuestos derivados de 1,4-dihidrocromeno[4,3-c]-pirazol, 1h-pirazol[4,3-f o 3,4-f]-quinolina, 1h-benzo[g]-indazol, que median una afección por fxr; composiciones y combinaciones farmacológicas; útiles para el tratamiento de una enfermedad hepática, tales como colestasis intrahepática, inducida por los estrógenos, por fármacos, inducida por fármacos, asociada al embarazo, asociada a nutrición parenteral, entre otras.

Info

Publication number
CL2016000982A1
CL2016000982A1 CL2016000982A CL2016000982A CL2016000982A1 CL 2016000982 A1 CL2016000982 A1 CL 2016000982A1 CL 2016000982 A CL2016000982 A CL 2016000982A CL 2016000982 A CL2016000982 A CL 2016000982A CL 2016000982 A1 CL2016000982 A1 CL 2016000982A1
Authority
CL
Chile
Prior art keywords
induced
fxr
treatment
liver disease
compounds derived
Prior art date
Application number
CL2016000982A
Other languages
English (en)
Spanish (es)
Inventor
Chianelli Donatella
Molteni Valentina
Liu Xiaodong
Nelson John
Roland Jason
Rucker Paul
Tully David
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51982773&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2016000982(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CL2016000982A1 publication Critical patent/CL2016000982A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
CL2016000982A 2013-11-05 2016-04-25 Compuestos derivados de 1,4-dihidrocromeno[4,3-c]-pirazol, 1h-pirazol[4,3-f o 3,4-f]-quinolina, 1h-benzo[g]-indazol, que median una afección por fxr; composiciones y combinaciones farmacológicas; útiles para el tratamiento de una enfermedad hepática, tales como colestasis intrahepática, inducida por los estrógenos, por fármacos, inducida por fármacos, asociada al embarazo, asociada a nutrición parenteral, entre otras. CL2016000982A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361900013P 2013-11-05 2013-11-05

Publications (1)

Publication Number Publication Date
CL2016000982A1 true CL2016000982A1 (es) 2016-10-07

Family

ID=51982773

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016000982A CL2016000982A1 (es) 2013-11-05 2016-04-25 Compuestos derivados de 1,4-dihidrocromeno[4,3-c]-pirazol, 1h-pirazol[4,3-f o 3,4-f]-quinolina, 1h-benzo[g]-indazol, que median una afección por fxr; composiciones y combinaciones farmacológicas; útiles para el tratamiento de una enfermedad hepática, tales como colestasis intrahepática, inducida por los estrógenos, por fármacos, inducida por fármacos, asociada al embarazo, asociada a nutrición parenteral, entre otras.

Country Status (42)

Country Link
US (5) US9682939B2 (enExample)
EP (1) EP3065738B1 (enExample)
JP (1) JP6424231B2 (enExample)
KR (1) KR102350357B1 (enExample)
CN (1) CN105682656B (enExample)
AP (1) AP2016009165A0 (enExample)
AR (1) AR098316A1 (enExample)
AU (1) AU2014346919B2 (enExample)
BR (1) BR112016009630B1 (enExample)
CA (1) CA2927705C (enExample)
CL (1) CL2016000982A1 (enExample)
CR (1) CR20160212A (enExample)
CU (1) CU24375B1 (enExample)
CY (1) CY1120273T1 (enExample)
DK (1) DK3065738T3 (enExample)
EA (1) EA030430B1 (enExample)
ES (1) ES2670984T3 (enExample)
GT (1) GT201600085A (enExample)
HR (1) HRP20180817T1 (enExample)
HU (1) HUE039155T2 (enExample)
IL (1) IL245242B (enExample)
JO (1) JO3454B1 (enExample)
LT (1) LT3065738T (enExample)
MA (1) MA39088B1 (enExample)
MX (1) MX364834B (enExample)
MY (1) MY175903A (enExample)
NO (1) NO3105103T3 (enExample)
NZ (1) NZ719078A (enExample)
PE (1) PE20160682A1 (enExample)
PH (1) PH12016500777B1 (enExample)
PL (1) PL3065738T3 (enExample)
PT (1) PT3065738T (enExample)
RS (1) RS57179B1 (enExample)
SG (1) SG11201603026PA (enExample)
SI (1) SI3065738T1 (enExample)
SV (1) SV2016005192A (enExample)
TN (1) TN2016000143A1 (enExample)
TR (1) TR201807321T4 (enExample)
TW (1) TWI662027B (enExample)
UY (1) UY35818A (enExample)
WO (1) WO2015069666A1 (enExample)
ZA (1) ZA201602555B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344540B2 (en) 2016-02-22 2022-05-31 Novartis Ag Methods for treating liver disorders using FXR agonists

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
TWI698430B (zh) 2015-02-13 2020-07-11 南北兄弟藥業投資有限公司 三環化合物及其在藥物中的應用
US10351576B2 (en) 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors
NZ748641A (en) 2016-06-13 2020-04-24 Gilead Sciences Inc Fxr (nr1h4) modulating compounds
CA2968836C (en) 2016-06-13 2025-09-02 Gilead Sciences, Inc. FXR MODULATING COMPOUNDS (NR1H4)
JP6915050B2 (ja) * 2016-09-14 2021-08-04 ノバルティス アーゲー Ｆｘｒアゴニストの新規のレジーム
PE20190972A1 (es) * 2016-09-14 2019-07-09 Novartis Ag Combinacion de agonistas de fxr
MX2019003889A (es) * 2016-10-05 2019-08-12 Novartis Ag Composiciones de combinacion que comprenden agonistas de fxr para tratar o prevenir una enfermedad o trastorno fibrotico o cirrotico.
CN107973790A (zh) * 2016-10-22 2018-05-01 合帕吉恩治疗公司 杂环fxr调节剂
ES2982801T3 (es) 2017-03-28 2024-10-17 Gilead Sciences Inc Combinaciones terapéuticas para el tratamiento de las enfermedades hepáticas
WO2018226155A1 (en) * 2017-06-05 2018-12-13 National University Of Singapore Compounds useful in inhibiting human trefoil factor 3
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
JP2020533339A (ja) * 2017-09-13 2020-11-19 ノバルティス アーゲー Ｆｘｒアゴニストを含む組合せ
WO2019092171A1 (en) 2017-11-09 2019-05-16 Inflazome Limited Novel sulfonamide carboxamide compounds
CN111315733A (zh) 2017-11-09 2020-06-19 英夫拉索姆有限公司 新颖磺酰胺甲酰胺化合物
CN110128432B (zh) * 2018-02-02 2021-03-02 广东东阳光药业有限公司 含氮三环化合物及其在药物中的应用
WO2019166619A1 (en) 2018-03-02 2019-09-06 Inflazome Limited Novel compounds
US12168012B2 (en) 2018-07-25 2024-12-17 Novartis Ag NLRP3 inflammasome inhibitors
KR102692309B1 (ko) 2019-01-15 2024-08-07 길리애드 사이언시즈, 인코포레이티드 Fxr (nr1h4) 조정 화합물
US10610280B1 (en) 2019-02-02 2020-04-07 Ayad K. M. Agha Surgical method and apparatus for destruction and removal of intraperitoneal, visceral, and subcutaneous fat
WO2020172075A1 (en) 2019-02-19 2020-08-27 Gilead Sciences, Inc. Solid forms of fxr agonists
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
WO2021009332A1 (en) 2019-07-18 2021-01-21 Enyo Pharma Method for decreasing adverse-effects of interferon
TW202122078A (zh) 2019-09-06 2021-06-16 瑞士商諾華公司 使用lta4h抑制劑治療肝臟疾病之方法
IL293892A (en) 2020-01-15 2022-08-01 Inserm Institut National De La Sant? Et De La Rech M?Dicale Use of fxr agonists for treating an infection by hepatitis d virus
CN113387828A (zh) * 2020-03-14 2021-09-14 江巨东 一种阿利克仑中间体的制备方法
WO2022037663A1 (zh) * 2020-08-21 2022-02-24 苏州晶云药物科技股份有限公司 苯甲酸衍生物的新晶型及其制备方法
MX2023008365A (es) 2021-01-14 2023-10-04 Enyo Pharma Efecto sinérgico de un agonista de fxr e ifn para el tratamiento de infección por hbv.
TW202308629A (zh) 2021-04-28 2023-03-01 法商Ｅｎｙｏ製藥公司 使用fxr激動劑作為組合治療以增強tlr3激動劑之療效
UY40374A (es) 2022-08-03 2024-02-15 Novartis Ag Inhibidores de inflamasoma nlrp3
EP4577206A2 (en) * 2022-08-26 2025-07-02 Celmatix Inc. Novel modulators of fshr and uses thereof
WO2026133229A1 (en) 2024-12-20 2026-06-25 Novartis Ag Nlrp3 inflammasome inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050143449A1 (en) * 2002-11-15 2005-06-30 The Salk Institute For Biological Studies Non-steroidal farnesoid X receptor modulators and methods for the use thereof
DK2029547T3 (da) * 2006-05-24 2010-07-26 Lilly Co Eli FXR-agonister
JP2010504032A (ja) * 2006-09-15 2010-02-04 タレス アビオニクス インコーポレイテッド 航空機との間でコンテンツを無線で転送するシステム及び方法
TW200906823A (en) 2007-07-16 2009-02-16 Lilly Co Eli Compounds and methods for modulating FXR
CU24152B1 (es) * 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
SG11201603026PA (en) 2013-11-05 2016-05-30 Novartis Ag Compositions and methods for modulating farnesoid x receptors
US10351576B2 (en) 2015-04-30 2019-07-16 Novartis Ag Fused tricyclic pyrazole derivatives useful for farnesoid X receptors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11344540B2 (en) 2016-02-22 2022-05-31 Novartis Ag Methods for treating liver disorders using FXR agonists

Also Published As

Publication number Publication date
TWI662027B (zh) 2019-06-11
CA2927705C (en) 2021-09-21
US20210253534A1 (en) 2021-08-19
SV2016005192A (es) 2016-11-21
AU2014346919B2 (en) 2017-02-02
AP2016009165A0 (en) 2016-04-30
TN2016000143A1 (en) 2017-10-06
PH12016500777A1 (en) 2016-05-30
NZ719078A (en) 2018-07-27
KR20160079091A (ko) 2016-07-05
HUE039155T2 (hu) 2018-12-28
NO3105103T3 (enExample) 2018-05-12
MY175903A (en) 2020-07-15
CA2927705A1 (en) 2015-05-14
US11021446B2 (en) 2021-06-01
US10077240B2 (en) 2018-09-18
US20160340317A1 (en) 2016-11-24
CR20160212A (es) 2016-07-22
EA030430B1 (ru) 2018-08-31
EA201690930A1 (ru) 2016-08-31
IL245242A0 (en) 2016-06-30
BR112016009630B1 (pt) 2021-02-09
IL245242B (en) 2019-03-31
JO3454B1 (ar) 2020-07-05
US20200247757A1 (en) 2020-08-06
TW201612163A (en) 2016-04-01
US20170275256A1 (en) 2017-09-28
KR102350357B1 (ko) 2022-01-14
SI3065738T1 (en) 2018-06-29
RS57179B1 (sr) 2018-07-31
GT201600085A (es) 2019-07-19
SG11201603026PA (en) 2016-05-30
US9682939B2 (en) 2017-06-20
CU24375B1 (es) 2018-12-05
CN105682656A (zh) 2016-06-15
US20190062283A1 (en) 2019-02-28
AR098316A1 (es) 2016-05-26
CN105682656B (zh) 2019-11-05
PT3065738T (pt) 2018-06-04
CU20160063A7 (es) 2016-09-30
PE20160682A1 (es) 2016-07-23
CY1120273T1 (el) 2019-07-10
US10683271B2 (en) 2020-06-16
ZA201602555B (en) 2017-06-28
PH12016500777B1 (en) 2016-05-30
MA39088B1 (fr) 2018-06-29
MX2016005865A (es) 2016-07-13
JP2016535784A (ja) 2016-11-17
UY35818A (es) 2015-05-29
WO2015069666A1 (en) 2015-05-14
MA39088A1 (fr) 2017-07-31
TR201807321T4 (tr) 2018-06-21
MX364834B (es) 2019-05-08
AU2014346919A1 (en) 2016-05-12
JP6424231B2 (ja) 2018-11-14
LT3065738T (lt) 2018-05-10
BR112016009630A8 (pt) 2020-04-07
PL3065738T3 (pl) 2018-07-31
EP3065738A1 (en) 2016-09-14
HRP20180817T1 (hr) 2018-06-29
EP3065738B1 (en) 2018-02-28
DK3065738T3 (en) 2018-06-06
ES2670984T3 (es) 2018-06-04

Similar Documents

Publication Publication Date Title
CL2018003323A1 (es) Piridinas sustituidas con heteroarilo y métodos de uso.
SV2018005723A (es) Derivados de tiohidantoina substituidos como antagonistas del receptor de androgenos
CO2018006662A2 (es) Agonistas del receptor de apelina y métodos de uso
CL2017003258A1 (es) Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CL2018000953A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
NI201700095A (es) Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos
MX2018007932A (es) Composiciones de inoculante estables y metodos para producir las mismas.
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
BR112016007375A2 (pt) conjuntos de procedimentos para habilitar comunicações sem fio com o uso de estruturas de subquadro que tenham diferentes durações de subquadro
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
ECSP16061758A (es) Moduladores de tetrahidropiridopirazinas de gpr6
GT201400297A (es) Nuevos derivados tienopirimidina, un proceso para su preparación y composiciones farmacéuticas que los contienen
CL2015002865A1 (es) Composiciones de limpieza que contienen una poliéteramina
EA201391602A1 (ru) Контролируемое высвобождение иммунодепрессантов из синтетических наноносителей
DOP2015000270A (es) Potenciador de inhibidores del homólogo de zeste
BR112015028870A2 (pt) estruturas fibrosas hidroentrelaçadas
GT201400230A (es) Necleòsidos de espìrooxetano de uracilo
BR112015019432A2 (pt) Compostos de tubulisina, métodos de produção e uso
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
CL2013000714A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso de preparacion; composicion farmaceutica que los comprende; metodo de tratamiento; y uso del compuesto para tratar enfermedades tales como diabetes tipo 2, sindrome metabolico, dislipidemia, hipertension y esquizofrenia, entre otras.
PL3221333T3 (pl) Steroidy, 6.alfa-alkilo-3,7-diony jako związki pośrednie do wytwarzania steroidowych modulatorów fxr
CR20160433A (es) Nuevos compuestos
PH12015502665A1 (en) Improvements in or relating to organic compounds
CL2008003095A1 (es) Procedeimiento de preparacion de dihidrotienopirimidas; uno de los compuestos intermediarios considerados; y el procedimiento de preparacion de dicho compuesto intermediario.